Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
5.37
-0.07 (-1.29%)
At close: Oct 3, 2025, 4:00 PM EDT
5.26
-0.11 (-2.05%)
After-hours: Oct 3, 2025, 7:24 PM EDT
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-$629,830
Market Cap
13.54M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25 | -8 | -24.24% |
| Dec 31, 2023 | 33 | 2 | 6.45% |
| Dec 31, 2022 | 31 | 2 | 6.90% |
| Dec 31, 2021 | 29 | 2 | 7.41% |
| Dec 31, 2020 | 27 | -2 | -6.90% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMNN News
- 12 days ago - IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift - GlobeNewsWire
- 15 days ago - IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research - GlobeNewsWire
- 5 weeks ago - IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement - GlobeNewsWire
- 2 months ago - IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call - GlobeNewsWire
- 2 months ago - Imunon, Inc. (IMNN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - IMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer - GlobeNewsWire
- 2 months ago - IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025 - GlobeNewsWire